Bhagwangar Dhanishtha Kika; and Smith, Matthew R.; O’Rourke, J. S. (Editor)
February 12, 2018
Clinical tests showed cholesterol drug Vytorin® was not living up to the claims of the producers, Schering-Plough and Merck. Consumers could receive a virtually equivalent drug for one-third of the cost. The problem facing Schering-Plough was to find the best methods to reach its stakeholders and ensure them that their concerns will be addressed in a timely and effective manner. This case has health, financial, and legal ramifications for stakeholders. 11 pp. Case #08-11 (2008).